Name: CANF Cash Flow - Can-fite Biopharma Operating Cash & FCF | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Operating Cash Flow, Investing Cash Flow, Financing Cash Flow, Capital Expenditures, Free Cash Flow, Dividends Paid, Stock Buybacks, Net Change in Cash

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

CANF - Can-fite Biopharma Ltd.

USD | NYSE | Healthcare

CANF Cash Flow - Can-fite Biopharma Operating Cash & FCF | Ledgeburg

(in millions of USD)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Net Income
Net Income	(9.8)	(7.9)	(7.6)	(10.2)	(12.6)	(14.4)	(12.6)	(6.6)	(4.8)	(8.4)	(6.5)
Cash From Operating Activities
Depreciation & Amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Amortization Of Intangibles	-
Cash From Investing Activities
Capital Expenditures	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	-
Acquisitions	-	-
Cash From Financing Activities
Debt Issued	-	-	-	-	-	-	-	-	-	-	-
Debt Repaid	-	-	-
Change In Cash & Equivalents
Effects Of Exchange Rate Changes	0.0	(0.0)	0.1	(0.1)	0.0	(0.0)	0.0	(0.1)	(0.1)	-	-
Net Change In Cash	0.7
Free Cash Flow
Free Cash Flow	(9.0)	(7.6)	(8.4)	(10.8)	(9.9)	(12.1)	(11.1)	(4.2)	(9.0)	-	-
Free Cash Flow To Equity	-	-	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Cash Flow Statement